Advanced Utilization Management Program
National CooperativeRx constantly monitors the pharmaceutical marketplace for new therapies in the pipeline. We have implemented our opt-in Advanced Utilization Management program to offer our member groups an opportunity to employ our recommendations on a quarterly basis to better adapt their plans to the rapidly changing market. We are currently focusing on the management of the following categories.
Target Drug: Prevymis
Continuous Blood Glucose Monitors (CGM), where covered
Target Drugs: Dexcom Receiver
Target Drug: Sucraid
Oral Allergy Immunotherapy, where covered
Target Drugs: Grastek, Odactra, Oralair, Ragwitek, Palforzia
Target Drugs: Nurtec, Ubrelvy, Reyvow
Target Drugs: Sunosi, Xyrem
This page was last updated on February 9, 2021.